Dallas Mavericks reportedly planning to trade Kyrie Irving after ACL return

Kyrie Irving has not played in an NBA game since March 3, 2026. More than a year after ACL surgery, the Dallas Mavericks are reportedly treating his rehabilitation as an asset-management window. According to an in-depth personnel analysis, the franchise wants Irving to return, play 15 to 20 games to prove his fitness, and then be traded before the February 2027 deadline. That plan is the rational final step after the Luka Doncic trade to the Los Angeles Lakers in February 2026. The most overlooked detail is Irving's age: 34. The three-year, $126 million contract he signed in 2026 no longer fits a roster built around No. 1 pick Cooper Flagg. Irving is easy to remember for off-court noise, but people forget that before the ACL tear he was still an All-Star-caliber guard averaging 24.7 points, 4.8 rebounds and 4.6 assists. The question is not whether he can still score, but how much explosion remains for a guard who relies on burst and change of pace after a major knee injury at 34. Dallas is not a sentimental operation. General manager Nico Harrison has shown that with the Doncic trade. Rejecting all summer offers for Irving was not loyalty; it was valuation. Selling him during active rehab would have returned pennies. Waiting for him to prove health on the court could turn those pennies into one or two first-round picks plus a young player. Still, the "prove fitness, then sell" approach carries a paradox. If the Mavericks limit Irving's minutes to protect the asset, his numbers may not reach their ceiling. If they let him play freely to boost stats, the risk of reinjury rises. Smart teams will study workload charts before committing valuable picks. There is a thin line between "healthy" and "being showcased." Dallas also cannot afford to lose Irving for nothing. They have already sent a 2026 first-rounder to Brooklyn and a 2029 pick to the Lakers. Their draft-pick pool is thin. Trading Irving is the only way to convert an expiring contract into rebuilding capital. Flagg's rookie-scale deal creates salary flexibility, but a rebuild cannot rely on one teenager and hope. Stylistically, Irving no longer fits the timeline. Flagg needs touches and a low-pressure development environment. Keeping Irving would consume 25-30% of possessions and make the offense dependent on a guard recovering from a serious injury. It is not that Irving's game is harmful; it is simply out of sync with the franchise clock. Any deal must satisfy CBA salary-matching rules. Irving earns more than $40 million per season, so partners need matching contracts or the Mavericks need a traded-player exception. That narrows the market. The February 2027 deadline is ideal because contenders tend to overpay for proven playoff scorers. Nobody knows whether Irving will return to his old self. John Wall never regained his peak after a similar injury; Klay Thompson lost some burst but survived on shooting. Irving's handle gives him more margin than Wall, but his game depends on footwork and separation. If the lost burst outweighs his instincts, every potential buyer faces early-decline risk. There is also a human dynamic. Irving knows he is being showcased. That can ignite a scoring fire, or it can create quiet resistance if he feels rushed. His relationship with the medical staff will be an invisible variable. A locker room that lost Luka, carries a 19-year-old phenom, and watches a veteran being marketed becomes anything but calm. The Western Conference is full of ascending young teams like Oklahoma City and Houston. The Mavericks are resetting their contention clock. Trading Irving does not solve every problem, but it unlocks space and touches for the next generation. If executed well, the move should be viewed as planned surgery, not an emotional cut. There is one scenario most people avoid: if Irving returns at an All-Star level and Flagg exceeds expectations, would Dallas change course? The answer depends on Harrison's resolve. But the era when a struggling club needed a doctor, a plan and someone willing to tell the truth is over. The Mavericks already have all three. They are telling everyone what most teams hide: no one is untouchable. When the February 2027 trade window opens, some contender will enter with picks in hand. They will study imaging, workout clips and Irving's movement in showcase games. Dallas no longer needs to convince anyone that it will sell early. The Mavericks need to show the opposite: even when Irving is healthy, leaving is the only option. This is not a story of a washed-up star. It is the story of a franchise setting its clock toward 2030.